Lucent Diagnostics Launches LucentAD Complete Blood Test for Alzheimer’s Detection
Slice of Healthcare Team
10/30/2024
Key Highlights
- LucentAD Complete by Lucent Diagnostics enhances Alzheimer's detection using a multi-marker approach.
- Reduces patients in the “intermediate zone” of uncertainty by threefold, cutting the need for invasive follow-up tests.
- Utilizes five AD biomarkers (p-Tau 217, Aβ42/40, NfL, GFAP) for better classification accuracy.
- Backed by Alzheimer’s Drug Discovery Foundation funding and tested in over 1,000 patients across three independent cohorts.
Source: Business Wire
Notable Quotes
“ In over 1,000 patients across three independent clinical cohorts, we achieved guideline performance standard for a blood-based Alzheimer’s diagnostic test, while significantly increasing conclusive results for more patients versus p-Tau 217 alone. ”
Masoud Toloue, CEO at Quanterix
“ Alzheimer’s is a multifaceted disease and as such, we will need a multi biomarker approach to detect the various underlying pathologies. ”
Howard Fillit, MD, Chief Science Officer at Alzheimer’s Drug Discovery Foundation
